Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cish inactivated til
- Development stage
- Unknown
- Lead developer
- Intima Bioscience
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CISH inactivated TIL refers to a cell therapy product consisting of autologous tumor-infiltrating lymphocytes (TILs) that have been genetically engineered ex vivo to inactivate the cytokine-inducible SH2-containing protein (CISH) gene using CRISPR/Cas9 technology. CISH is an intracellular immune checkpoint and negative regulator of T-cell receptor signaling. Inactivation of CISH enhances the anti-tumor activity and functional avidity of T cells by removing this inhibitory pathway, resulting in improved recognition and killing of cancer cells. This therapy is being developed primarily for solid tumors such as metastatic non-small cell lung cancer (NSCLC) and gastrointestinal cancers[2][3][5][8]. The approach aims to boost the efficacy of adoptive cell transfer immunotherapy by overcoming intrinsic resistance mechanisms within patient-derived T cells.
- Other names
- autologous cish-inactivated tilscish-inactivated autologous tilscish crispr til
02
Targets
CISH (Cytokine-inducible SH2-containing protein)
Beyond the preview
Go deeper on cish inactivated til.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cish inactivated til.